BevacizumabRecent, repeatedEvidence- NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Bevacizumab” · registered Sep 2026
- NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Bevacizumab” · registered Mar 2026
- NCT07479485 · Lepu Biopharma Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Mar 2026
- NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Bevacizumab” · registered Jan 2026
- NCT06986785 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered May 2025
| Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others | 1618 studies | 1517 studies | comparator 3 · background 18 |
lenvatinibRecent, repeatedEvidence- NCT07836530 · BeOne Medicines · Phase 3 · live · comparator · “Lenvatinib” · registered Sep 2026
- NCT07540832 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Lenvatinb” · registered Apr 2026
- NCT07282509 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Lenvatinib Mesilate Capsules” · registered Nov 2025
- NCT07219459 · CatalYm GmbH · Phase 2 · live · background · “Lenvatinib” · registered Oct 2025
- NCT06986785 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Lenvatinib” · registered May 2025
| Eisai Co., Ltd.63% of its industry studiesUS: Eisai Co., Ltd. (FDA 2015)EU: Eisai Co., Ltd. (EMA 2015) | 1113 studies | 1214 studies | background 17 · comparator 4 |
NivolumabRecent, repeatedEvidence- NCT07219459 · CatalYm GmbH · Phase 2 · live · background · “Nivolumab” · registered Oct 2025
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
- NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Nivolumab” · registered May 2023
- NCT05257590 · TaiRx, Inc. · Phase 2 · live · background · “Nivolumab Injection [Opdivo]” · registered Feb 2022
- NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Nivolumab” · registered Jan 2022
| Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015) | 77 studies | 88 studies | background 14 |
pembrolizumabRecent, repeatedEvidence- NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
- NCT07282509 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Pembrolizumab Injection” · registered Nov 2025
- NCT06400160 · Twinpig Biolab, Inc. · Phase 2 · live · background · “Keytruda” · registered Apr 2024
- NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
- NCT05440708 · Tvardi Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2022
| Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015) | 66 studies | 55 studies | background 7 |
atezolizumabRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
- NCT06921785 · AstraZeneca · Phase 3 · live · comparator · “Atezolizumab” · registered Mar 2025
- NCT06109272 · AbbVie · Phase 3 · live · comparator · “Atezolizumab” · registered Oct 2023
- NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Feb 2023
- NCT05440708 · Tvardi Therapeutics, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Jun 2022
| Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017) | 66 studies | 55 studies | background 5 · comparator 2 |
sintilimabRecent, repeatedEvidence- NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Sintilimab” · registered Sep 2026
- NCT06618664 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Sintilimab” · registered Sep 2024
- NCT06530251 · Akeso · Phase 2 · live · comparator · “Sintilimab Injection” · registered Jul 2024
- NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Sintilimab” · registered Jul 2023
| Innovent Biologics, Inc.73% of its industry studies | 44 studies | 44 studies | comparator 4 |
IpilimumabRecent, repeatedEvidence- NCT07227012 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
- NCT06841185 · Fosun Pharma · Phase 3 · live · comparator · “US-sourced YERVOY®” · registered Feb 2025
- NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
- NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Ipilimumab” · registered Jan 2022
- NCT03241173 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Aug 2017
| Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011) | 44 studies | 33 studies | background 5 · comparator 1 |
SorafenibRecent, repeatedEvidence- NCT07836530 · BeOne Medicines · Phase 3 · live · comparator · “Sorafenib” · registered Sep 2026
- NCT06309485 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Sorafenib 400 mg PO, BID” · registered Mar 2024
- NCT05822752 · AbbVie · Phase 2 · live · comparator · “Sorafenib” · registered Apr 2023
- NCT05033522 · Mirror Biologics, Inc. · Phase 3 · comparator · “Sorafenib” · registered Aug 2021
- NCT04985136 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Sorafenib” · registered Jul 2021
| Bayer69% of its industry studiesUS: off-patent, 5 generics marketedEU: off-patent, 1 generic authorized | 33 studies | 88 studies | comparator 23 · background 18 |
CapecitabineRecent, repeatedEvidence- NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Capecitabine” · registered Mar 2026
- NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
- NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jul 2023
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Aug 2021
- NCT03563170 · ImmunityBio, Inc. · Phase 2 · background · “Capecitabine” · registered May 2018
| Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized | 33 studies | 33 studies | background 5 |
OxaliplatinRecent, repeatedPhase 4 trial recordedEvidence- NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Oxaliplatin” · registered Mar 2026
- NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Oxaliplatin injection” · registered Jan 2026
- NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Oxaliplatin injection” · registered Jul 2023
- NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Oxaliplatin” · registered Aug 2021
| Sanofi35% of its industry studies | 33 studies | 33 studies | background 4 |
durvalumabRecent, repeatedEvidence- NCT06109272 · AbbVie · Phase 3 · live · comparator · “Durvalumab” · registered Oct 2023
- NCT06111326 · Biocity Biopharmaceutics Co., Ltd. · Phase 2 · live · background · “Durvalumab injection” · registered Oct 2023
- NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Durvalumab” · registered Feb 2023
| AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018) | 33 studies | 33 studies | comparator 1 · background 2 |
regorafenibRecent, repeatedEvidence- NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · comparator · “Regorafenib” · registered Jan 2026
- NCT07310173 · Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 2 · live · comparator · “Regorafenib Tablets” · registered Dec 2025
- NCT04985136 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Regorafenib” · registered Jul 2021
| Bayer80% of its industry studiesUS: Bayer (FDA 2012)EU: Bayer (EMA 2013) | 22 studies | 22 studies | comparator 3 |
Abiraterone AcetateRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Abiraterone” · registered May 2026
- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
| Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized | 22 studies | 22 studies | background 2 |
enzalutamideRecent, repeatedEvidence- NCT07620574 · Exelixis · Phase 3 · live · background · “Enzalutamide” · registered May 2026
- NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
| Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized | 22 studies | 22 studies | background 2 |